Exelixis, Inc. received FDA approval of CABOMETYX for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with OPDIVO.
- Approval is based on results from CheckMate -9ER trial
- Exelixis shares currently up about 2.4%
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2021 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.